Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Zachary Cohen

Podiatrist, Foot & Ankle Surgery Cleburne, TX Doctor of Podiatric Medicine

NPI 1831694124 CMS profile 9705772

2010 W Katherine P Raines Rd Ste 300, Cleburne, TX 76033

Open in the dashboard

General payments

$5,811

75 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zachary Cohen of Cleburne, TX is reported in the CMS Open Payments database as having received $5,811 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $659 8
2024 General $536 14
2023 General $335 6
2022 General $1,087 15
2021 General $3,045 31
2020 General $150 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zachary Cohen
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Zachary Cohen were reported at $659. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Zachary Cohen Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $150 $191 $62–$691 $114
2021 $3,045 $329 $104–$1,341 $132
2022 $1,087 $419 $125–$1,611 $149
2023 $335 $377 $128–$1,164 $160
2024 $536 $394 $134–$1,168 $164
2025 $659 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Globus Medical, Inc. $2,140 17 payments
  2. Stryker Corporation $847 11 payments
  3. Pylant Medical $583 7 payments
  4. Orthofix Medical, Inc. $475 5 payments
  5. Smith+Nephew, Inc. $429 5 payments
  6. Anika Therapeutics, Inc. $171 2 payments
  7. Bioventus LLC $170 2 payments
  8. Bone Support Inc. $150 1 payment
  9. Triad Life Sciences Inc. $122 1 payment
  10. DePuy Synthes Sales Inc. $103 1 payment
  11. Other $621 23 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,387 69 payments
  2. Travel and Lodging $1,425 6 payments
Products named General payments · program years 2020–2025
  1. Clavical Fixation (16-186) $1,291 3 payments
  2. VARIAX $317 2 payments
  3. TrueLok $280 2 payments
  4. AUGMENT INJECTABLE $246 4 payments
  5. ANTHEM $244 3 payments
  6. Ankle Fracture System $216 4 payments
  7. TL-HEX TRUELOK HEXAPOD SYSTEM $194 3 payments
  8. Distal Tibia Plating $171 2 payments
  9. T2 $167 1 payment
  10. Mini Fragment System $150 1 payment
  11. Other $2,277 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

364

Median for Podiatry: 160

Drug cost

$4,185

Median for Podiatry: $2,368

Branded share of claims

37.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 44 $592
Ciclopirox Generic 18 $576
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 67 $565
Cyclobenzaprine Hcl Generic 34 $502
Gabapentin Generic 40 $391
Methylprednisolone Generic 45 $351
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 25 $328
Cephalexin Generic 35 $268
Ciprofloxacin Hcl Generic 12 $218
Doxycycline Hyclate Generic 13 $175

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$611,125

Of which drugs: $543,907

Medicare patients

273

Average age 73

Services billed

1,817

137 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 53%
Ischemic heart disease 34%
Chronic kidney disease 34%
Depression 30%
COPD 25%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 182 $138

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record